We were delighted to catch up with editorial board member Prof Elias Jabbour (MD Anderson Cancer Center, Houston, TX, USA) to discuss his presentation at the American Society of Hematology (ASH) Annual Meeting on dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia from the PACE and Optic trials.
Questions
1. What are the unmet needs in the management of patients with treatment-resistant chronic-phase chronic myeloid leukemia? 00:11-00:40
2. Could you tell us a little about ponatinib and the clinical evidence supporting its use in this treatment setting? 00:40-01:24
3. What were the objectives of the analysis of data from the PACE and OPTIC trials? 01:24-02:36
4. What were the efficacy findings from the dose reduction strategies of the two studies? 02:38-03:48
5. What are the clinical implications of these findings and what further research is needed? 03:48-04:30
Speaker Disclosure: Elias Jabbour has no financial or non-financial conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 63rd ASH Annual Meeting & Exposition
